Caris Life Sciences (CAI) Stock: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$24.34
0.30 (1.25%)
â˛
5d:
-3.87%
30d:
+9.34%
90d:
+35.22%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CAI is fairly priced but lacks strong directional signals. At 8.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CAI is fairly priced but lacks strong directional signals. At 8.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $24.34, which is considered fair relative to its 30-day fair value range of $20.32 to $26.32. From a valuation perspective, the stock is trading at a premium (Forward PE: 64.8) compared to its historical average (51.1). At these levels, the market is pricing in 8.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAI is in a uptrend. Immediate support is located at $23.20, while resistance sits at $26.75.
Market Sentiment: CAI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.54 (+13.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAI is in a uptrend. Immediate support is located at $23.20, while resistance sits at $26.75.
Market Sentiment: CAI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.54 (+13.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$20.32 -
$26.32
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
46.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($27.54)
- NEUTRAL: Trading at premium valuation - market expects 8.2% growth which is achievable
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$20.32 -
$26.32
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$23.20
Resistance Level
$26.75
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
64.80
Wall Street Target
$27.54
(+13.1%)
Revenue Growth (YoY)
45.4%
Profit Margin
10.6%
Valuation Premium vs History
+8.2% premium
PE vs Historical
64.8 vs 51.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.2%
(market-implied from PE analysis)
1-Year Target
$26.34
(+8%)
2-Year Target
$28.50
(+17%)
3-Year Target
$30.83
(+27%)
3-Yr Target (if PE normalizes)
(PE: 65â51)
PE COMPRESSION
$24.31
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 64.8, Growth: 171.2%)
$82.15
(+238%)
Base:
(SPY PE: 20.2, Growth: 171.2%)
$25.57
(+5%)
Bear:
(PE: 17.1, Growth: 171.2%)
$21.73
(-11%)
đ
Valuation based on Current Earnings
Trailing PE: 2.51 | Current EPS (TTM): $9.59
Bull Case
$13.22
(-46%)
Analyst growth -50.0%, PE expands to 2.8
Base Case
$12.02
(-51%)
Market implied -50.0%, PE stable at 2.5
Bear Case
$16.35
(-33%)
Severe decline -20.0%, PE contracts to 2.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 11, 2026 9:16 PM ET
Data refreshes hourly during market hours. Next update: 10:16 PM
Data refreshes hourly during market hours. Next update: 10:16 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |